Characterization of Human Striatal A₂-Adenosine Receptors Using Radioligand Binding and Photoaffinity Labeling

References

• Lohse M. J., Elger B., Lindenborn-Fotinos J., Klotz K.-N., Schwabe U. Separation of solubilized A2 adenosine receptors of human platelets from non-receptor [3H]NECA binding sites by gel filtration. Naunyn-Schmiedeberg's Arch. Pharmacol. 1988; 337: 64–68
   Google Scholar
• Olsson R. A., Pearson J. D. Cardiovascular purinoceptors. Physiol. Rev. 1990; 70: 761–845
   PubMed Web of Science ®Google Scholar
• Hutchison A. J., Webb R. L., Oei H. H., Ghai G. R., Williams M. CGS 21680C, an A2 selective adenosine receptor agonist with preferential hypotensive activity. J. Pharmacol. Exp. Ther. 1989; 251: 47–55
   PubMed Web of Science ®Google Scholar
• Phillis J. W. Purines in Cellular Signalling: Targets for New Drugs, K. Jacobson, J. Daly, V. Manganiello. Springer-Verlag, New York, NY 1990; 41–47
   Google Scholar
• Jarvis M. F., Jackson R. H., Williams M. Autoradiographic characterization of high affinity adenosine A2 receptors in the rat brain. Brain Res. 1989; 484: 111–118
   PubMed Web of Science ®Google Scholar
• Nikodijevic O., Daly J. W., Jacobson K. A. Characterization of the locomotor depression produced by an A2-selective adenosine agonist. FEBS Letters 1990; 261: 67–70
   PubMed Web of Science ®Google Scholar
• Barrington W. W., Jacobson K. A., Williams M., Hutchison A. J., Stiles G. L. Identification of the A2 adenosine receptor binding subunit by photoaffinity crosslinking. Proc. Nat. Acad. Sci. USA 1989; 86: 6572–6576
   PubMed Web of Science ®Google Scholar
• Barrington W. W., Jacobson K. A., Stiles G. L. The glycoprotein nature of the A2 adenosine receptor binding subunit. Mol. Pharmacol. 1990; 38: 177–183
   Google Scholar
• Nanoff C., Jacobson K. A., Stiles G. L. The A2 adenosine receptor: guanine nucleotide modulation of agonist binding is enhanced by proteolysis. Mol. Pharmacol. 1991; 39: 130–135
   PubMed Web of Science ®Google Scholar
• Maenhaut C., van Sande J., Libert F., Abramowicz M., Parmentier M., Vanderhaegen J.-J., Dumont J. E., Vassart G., Schiffmann S. RDC8 codes for an adenosine A2 receptor with physiological constitutive activity. Biochem. Biophys. Res. Comm. 1990; 173: 1169–1178
   PubMed Web of Science ®Google Scholar
• Jacobson K. A., Kirk K. L., Padgett W. L., Daly J. W. Functionalized congeners of adenosine: Preparation of analogues with high affinity for adenosine receptors. J. Med. Chem. 1985; 28: 1341–1346
   PubMedGoogle Scholar
• Jacobson K. A., Barrington W. W., Pannell L. K., Jarvis M. F., Ji X.-D., Williams M., Hutchison A. J., Stiles G. L. Agonist-derived molecular probes for A2-adenosine receptors. J. Mol. Recognition 1989; 2: 170–178
   Google Scholar
• Bruns R. F., Fergus J. H., Badger E. W., Bristol J. A., Santay L. A., Hays S. J. PD 115 199: an antagonist ligand for adenosine A2 receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1987; 335: 64–69
   Google Scholar
• Bruns R. F. Purines in Cellular Signalling: Targets for New Drugs, K. Jacobson, J. Daly, V. Manganiello. Springer-Verlag, New York, NY 1990; 126–135
   Google Scholar
• Williams M., Francis J. E., Ghai G. R., Braunwalder A., Psychyos S., Stone G. A., Cash W. D. Biochemical characterization of the triazoloquinazoline, CGS 15943 a novel non-xanthine adenosine antagonist. J. Pharmacol. Exp. Ther. 1987; 241: 415–420
   PubMed Web of Science ®Google Scholar
• Sarges R., Howard H. R., Browne R. G., Lebel L. A., Seymour P. A., Koe B. K. 4-Amino[1,2,4]triazolo[4,3-a]quinoxalines – a novel class of potent adenosine receptor antagonists and potential rapid onset anti-depressants. J. Med. Chem. 1990; 33: 2240–2254
   PubMed Web of Science ®Google Scholar
• Jarvis M. F., Schutz R., Hutchison A. J., Do E., Sills M. A., Williams M. [3H]CGS 21680 an A2 selective adenosine receptor agonist directly labels A2 receptors in rat brain tissue. J. Pharmacol. Exp. Ther. 1989; 251: 888–893
   PubMed Web of Science ®Google Scholar
• Jacobson K. A., Ukena D., Kirk K. L., Daly J. W. [3H]Xanthine amine congener of 1,3-dipropyl-8-phenylxanthine: an antagonist radioligand for adenosine receptors. Proc. Natl. Acad. Sci. U. S. A. 1986; 83: 4089–4093
   PubMed Web of Science ®Google Scholar
• Ukena D., Jacobson K. A., Kirk K. L., Daly J. W. A [3H]amine congener of 1,3-dipropyl-8-phenyl xanthine – a new radioligand for A2 adenosine receptors of human platelets. FEBS Lett. 1986; 199: 269–274
   Google Scholar
• Ji X.-D., Stiles G. L., Jacobson K. A. [3H]XAC (xanthine amine congener) is a radioligand for A2-adenosine receptors in rabbit striatum. Neurochem. Internat. 1991; 18: 207–213
   Google Scholar
• Cheng Y.-C., Prusoff W. H. Relationship between the inhibition constant (Ki) and the concentration of inhibitor which causes 50 percent inhibition (IC50) of an enzyme reaction. Biochem. Pharmacol. 1973; 22: 3099–3108
   PubMed Web of Science ®Google Scholar
• Ramkumar V., Barrington W. W., Jacobson K. A., Stiles G. L. Demonstration of both A1 and A2 adenosine receptors in DDT1 MF-2 smooth muscle cells. Mol. Pharmacol. 1990; 37: 149–156
   Google Scholar
• Bruns R. F., Lu G. H., Pugsley T. A. Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. Mol. Pharmacol. 1986; 29: 331–346
   PubMed Web of Science ®Google Scholar
• Deckert J., Morgan P. F., Bisserbe J. C., Jacobson K. A., Kirk K. L., Daly J. W., Marangos P. J. Autoradiographic localization of mouse brain adenosine receptors with an antagonist ([3H]xanthine amine congener) ligand probe. Neurosci. Lett. 1988; 86: 121–126
   PubMed Web of Science ®Google Scholar
• Reynaud D., Gharib A., Lagarde M., Sarda M. Characterization of A-2 receptors in postmortem human pineal gland. J. Neurochem. 1990; 55: 1316–1321
   Google Scholar
• Wan W., Sutherland G. R., Geiger J. D. Binding of the adenosine A2 receptor ligand [3H]CGS21680 to human and rat brain: Evidence for multiple affinity sites. J. Neurochem 1990; 55: 1763–1771
   PubMed Web of Science ®Google Scholar
• Stone G. A., Jarvis M. F., Sills M. A., Weeks B., Snowhill E. W., Williams M. Species differences in high-affinity adenosine A2 binding sites in striatal membranes from mammalian brain. Drug Devel. Res. 1988; 15: 31–46
   Google Scholar
• Ferkany J. W., Valentine H. L., Stone G. A., Williams M. Adenosine A1 receptors in mammalian brain: species differences in their interactions with agonists and antagonists. Drug Dev. Res. 1986; 9: 85–93
   Web of Science ®Google Scholar
• Nakata H. Purification of the A1-adenosine receptor from rat brain membranes. J. Biol. Chem. 1989; 264: 16545–16551
   PubMed Web of Science ®Google Scholar
• Olah M. E., Jacobson K. A., Stiles G. L. Purification and characterization of bovine cerebral cortex A1 adenosine receptor. Arch. Biochem. Biophys. 1991; 283: 440–446
   Google Scholar
• Bridges A. J., Bruns R. F., Ortwine D. G., Pribe S. R., Szotek D. L., Trivedi B. K. N6-[2(3,5-dimethoxyphenyl)-2-(2-methylphenyl)-ethyl]-adenosine and its uronamide derivatives. Novel adenosine agonists with both high affinity and high selectivity for the adenosine A2 receptor. J. Med. Chem. 1988; 31: 1282–1285
   PubMed Web of Science ®Google Scholar
• Lohse M. J., Klotz K.-N., Schwabe U., Cristalli G., Vittori S., Grifantini M. 2-Chloro-N6-Cyclopentyladenosine: a highly selective agonist at A1 adenosine receptors. Naunyn-Schmiedeberg's Arch. Pharmacol. 1988; 337: 687–689
   Google Scholar
• Cooper D. M. F. Adenosine Receptors, D. Cooper, C. Londos. Alan R. Liss, Inc., New York, NY 1987; 63–74
   Google Scholar